[Effects of simultaneous transplant of foetal mesencephalic cells in the striatum and the subthalamic nucleus of hemiparkinsonian rats].
BACKGROUND
The main strategy followed in neural transplants as a method of treatment for Parkinson s disease, both experimental and clinical, has been to introduce foetal mesencephalic cells into the target area: the striatum. However, when the dopaminergic cells in the substantia nigra degenerate, not only is the dopaminergic innervation of the striatum affected but also other nuclei: globus pallidus, substantia nigra, substantia nigra pars reticulata and subthalamic nucleus. A series of data from pharmacological and physiological studies offer strong evidence that the dopamine released in these nuclei may play an important role in regulating the output nuclei of the basal ganglia.


OBJECTIVE
To evaluate the effect of transplanting foetal mesencephalic cells on the behaviour of 6 OH DA rats when introduced into the striatum and the subthalamic nucleus.


METHODS
6 OH DA was used to induce lesions in the substantia nigra of rats, which were divided into several experimental groups. The rotating activity induced by D amphetamine (5 mg/kg, intraperitoneally) and apomorphine (0.05 mg/kg, subcutaneously) was evaluated before and three months after the transplant in all the experimental groups, except in the control group of healthy rats. The hemiparkinsonian rats received a total of 350,000 foetal ventral mesencephalic cells, which were implanted within small deposits in the striatum (8) and in the subthalamic nucleus (4).


CONCLUSIONS
Rotation induced by both drugs was significantly lower (p= 0.05) in animals that had had dopaminergic cells transplanted into the striatum body. No significant improvement in this behaviour was to be found when transplants were limited to just the subthalamus or, simultaneously, also to the striatum. A significant increase in rotating behaviour induced by apomorphine was observed in the group which received a transplant in just the subthalamus.
Centro Internacional de Restauración Neurológica (CIREN), La Habana, 11300, Cuba. nancy@neubas.sld.cu
N
N
Pavón-Fuentes
R
R
Macías-González
L
L
Blanco-Lezcano
L
L
Alvarez-González
L
L
Martínez-Martí
L
L
Castillo-Díaz
K
K
De La Cuétara Bernal
C
C
Díaz
L
L
Lorigados-Pedre
Y
Y
Coro
A Y
AY
García-Varona
J C
JC
Rosillo
E
E
Díaz
D018663:Adrenergic Agents / Q000494:pharmacology; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal; D016380:Brain Tissue Transplantation; D003913:Dextroamphetamine / Q000494:pharmacology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D016332:Fetal Tissue Transplantation; D008297:Male; D008636:Mesencephalon / Q000166:cytology* / Q000196:embryology / Q000637:transplantation; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000637:transplantation*; D016627:Oxidopamine / Q000633:toxicity; D010300:Parkinson Disease / Q000628:therapy*; D051381:Rats; D017208:Rats, Wistar; D012399:Rotation; D020531:Subthalamic Nucleus / Q000473:pathology / Q000601:surgery*; D014793:Visual Cortex / Q000473:pathology / Q000601:surgery*
D018663:Adrenergic Agents; D000978:Antiparkinson Agents; D016627:Oxidopamine; D001058:Apomorphine; D003913:Dextroamphetamine; D004298:Dopamine